Matches in SemOpenAlex for { <https://semopenalex.org/work/W2137397360> ?p ?o ?g. }
- W2137397360 endingPage "996" @default.
- W2137397360 startingPage "991" @default.
- W2137397360 abstract "ObjectiveCyclophosphamide has a role of decreasing high-sensitivity C-reactive protein in the treatment of autoimmune disorders. The effect of cyclophosphasmide on high-sensitivity C-reactive protein was investigated in myocardial ischemia/reperfusion rat.MethodsOpen-chest rats were submitted to 30 minutes of ischemia and followed for 3, 12, or 24 hours of reperfusion. All 72 rats survived and were divided into sham, ischemia/reperfusion (I/R) and cyclophosphamide groups, and each group included 3 time-point subgroups (3, 12, and 24 hours; n = 8 for each subgroup). Cyclophosphamide (0.75 g/m2) or saline was intraperitoneally administrated in the cyclophosphamide or I/R group. A polyethylene tube was inserted into the left ventricular cavity to detect left ventricular systolic pressure, left ventricular end-diastolic pressure, and maximum rate of rise or fall of left ventricular pressure. In the end, blood was collected for detection of high-sensitivity C-reactive protein, and hearts were harvested for histopathologic assessment and infarct size determination.ResultsCompared with the I/R group, rats treated with cyclophosphamide showed a significant recovery in myocardial function with improved left ventricular systolic pressure (88.27 ± 3.78 vs 68.62 ± 3.78 mm Hg at 3 hours, 92.04 ± 3.77 vs 63.74 ± 4.87 mm Hg at 12 hours, and 90.41 ± 3.98 vs 64.21 ± 4.88 mm Hg at 24 hours; P < .05, respectively). Left ventricular end-diastolic pressure and maximum rate of rise or fall of left ventricular pressure also had similar trends. Infarct size was reduced (26.1% ± 0.4% vs 40.4% ± 0.4% at 3 hours, 21.6% ± 0.4% vs 49.9% ± 0.4% at 12 hours, and 21.6% ± 0.4% vs 40.0% ± 0.4% at 24 hours; P < .01, respectively). Histopathologic damage score was attenuated (1.83 ± 0.14 vs 2.17 ± 0.14 at 3 hours, 2.33 ± 0.14 vs 3.17 ± 0.14 at 12 hours, and 2.83 ± 0.14 vs 3.83 ± 0.14 at 24 hours; P < .01, respectively). Plasma high-sensitivity C-reactive protein concentration was significantly reduced (29.28 ± 0.51 vs 32.26 ± 0.51 ng/mL at 3 hours, 29.06 ± 0.50 vs 31.8 ± 0.51 ng/mL at 12 hours, and 28.61 ± 0.51 vs 31.86 ± 0.51 ng/mL at 24 h; P < .01, respectively).ConclusionCyclophosphamide protects myocardial ischemia/reperfusion injury in the rat with a decrease in plasma concentration of high-sensitivity C-reactive protein. Cyclophosphamide has a role of decreasing high-sensitivity C-reactive protein in the treatment of autoimmune disorders. The effect of cyclophosphasmide on high-sensitivity C-reactive protein was investigated in myocardial ischemia/reperfusion rat. Open-chest rats were submitted to 30 minutes of ischemia and followed for 3, 12, or 24 hours of reperfusion. All 72 rats survived and were divided into sham, ischemia/reperfusion (I/R) and cyclophosphamide groups, and each group included 3 time-point subgroups (3, 12, and 24 hours; n = 8 for each subgroup). Cyclophosphamide (0.75 g/m2) or saline was intraperitoneally administrated in the cyclophosphamide or I/R group. A polyethylene tube was inserted into the left ventricular cavity to detect left ventricular systolic pressure, left ventricular end-diastolic pressure, and maximum rate of rise or fall of left ventricular pressure. In the end, blood was collected for detection of high-sensitivity C-reactive protein, and hearts were harvested for histopathologic assessment and infarct size determination. Compared with the I/R group, rats treated with cyclophosphamide showed a significant recovery in myocardial function with improved left ventricular systolic pressure (88.27 ± 3.78 vs 68.62 ± 3.78 mm Hg at 3 hours, 92.04 ± 3.77 vs 63.74 ± 4.87 mm Hg at 12 hours, and 90.41 ± 3.98 vs 64.21 ± 4.88 mm Hg at 24 hours; P < .05, respectively). Left ventricular end-diastolic pressure and maximum rate of rise or fall of left ventricular pressure also had similar trends. Infarct size was reduced (26.1% ± 0.4% vs 40.4% ± 0.4% at 3 hours, 21.6% ± 0.4% vs 49.9% ± 0.4% at 12 hours, and 21.6% ± 0.4% vs 40.0% ± 0.4% at 24 hours; P < .01, respectively). Histopathologic damage score was attenuated (1.83 ± 0.14 vs 2.17 ± 0.14 at 3 hours, 2.33 ± 0.14 vs 3.17 ± 0.14 at 12 hours, and 2.83 ± 0.14 vs 3.83 ± 0.14 at 24 hours; P < .01, respectively). Plasma high-sensitivity C-reactive protein concentration was significantly reduced (29.28 ± 0.51 vs 32.26 ± 0.51 ng/mL at 3 hours, 29.06 ± 0.50 vs 31.8 ± 0.51 ng/mL at 12 hours, and 28.61 ± 0.51 vs 31.86 ± 0.51 ng/mL at 24 h; P < .01, respectively). Cyclophosphamide protects myocardial ischemia/reperfusion injury in the rat with a decrease in plasma concentration of high-sensitivity C-reactive protein." @default.
- W2137397360 created "2016-06-24" @default.
- W2137397360 creator A5004648263 @default.
- W2137397360 creator A5009407813 @default.
- W2137397360 creator A5011723398 @default.
- W2137397360 creator A5021470676 @default.
- W2137397360 creator A5023874610 @default.
- W2137397360 creator A5034855917 @default.
- W2137397360 creator A5041536834 @default.
- W2137397360 creator A5043308787 @default.
- W2137397360 creator A5062157568 @default.
- W2137397360 creator A5063744024 @default.
- W2137397360 creator A5078061801 @default.
- W2137397360 date "2009-04-01" @default.
- W2137397360 modified "2023-09-30" @default.
- W2137397360 title "Cyclophosphamide protects against myocardial ischemia/reperfusion injury in rats: One of the therapeutic targets is high sensitivity C-reactive protein" @default.
- W2137397360 cites W1981062407 @default.
- W2137397360 cites W1994984554 @default.
- W2137397360 cites W2015137290 @default.
- W2137397360 cites W2018983048 @default.
- W2137397360 cites W2063034329 @default.
- W2137397360 cites W2071027536 @default.
- W2137397360 cites W2092360209 @default.
- W2137397360 cites W2094649779 @default.
- W2137397360 cites W2102435584 @default.
- W2137397360 cites W2111012807 @default.
- W2137397360 cites W2116118256 @default.
- W2137397360 cites W2120386620 @default.
- W2137397360 cites W2124312719 @default.
- W2137397360 cites W2128421277 @default.
- W2137397360 cites W2141211759 @default.
- W2137397360 cites W2152139387 @default.
- W2137397360 cites W2165405205 @default.
- W2137397360 cites W2182160369 @default.
- W2137397360 cites W2312254946 @default.
- W2137397360 cites W2317184793 @default.
- W2137397360 doi "https://doi.org/10.1016/j.jtcvs.2008.04.033" @default.
- W2137397360 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19327529" @default.
- W2137397360 hasPublicationYear "2009" @default.
- W2137397360 type Work @default.
- W2137397360 sameAs 2137397360 @default.
- W2137397360 citedByCount "2" @default.
- W2137397360 countsByYear W21373973602018 @default.
- W2137397360 crossrefType "journal-article" @default.
- W2137397360 hasAuthorship W2137397360A5004648263 @default.
- W2137397360 hasAuthorship W2137397360A5009407813 @default.
- W2137397360 hasAuthorship W2137397360A5011723398 @default.
- W2137397360 hasAuthorship W2137397360A5021470676 @default.
- W2137397360 hasAuthorship W2137397360A5023874610 @default.
- W2137397360 hasAuthorship W2137397360A5034855917 @default.
- W2137397360 hasAuthorship W2137397360A5041536834 @default.
- W2137397360 hasAuthorship W2137397360A5043308787 @default.
- W2137397360 hasAuthorship W2137397360A5062157568 @default.
- W2137397360 hasAuthorship W2137397360A5063744024 @default.
- W2137397360 hasAuthorship W2137397360A5078061801 @default.
- W2137397360 hasBestOaLocation W21373973601 @default.
- W2137397360 hasConcept C126322002 @default.
- W2137397360 hasConcept C164705383 @default.
- W2137397360 hasConcept C26635844 @default.
- W2137397360 hasConcept C2776694085 @default.
- W2137397360 hasConcept C2776755627 @default.
- W2137397360 hasConcept C2780114680 @default.
- W2137397360 hasConcept C42219234 @default.
- W2137397360 hasConcept C500558357 @default.
- W2137397360 hasConcept C541997718 @default.
- W2137397360 hasConcept C57900726 @default.
- W2137397360 hasConcept C71924100 @default.
- W2137397360 hasConcept C84393581 @default.
- W2137397360 hasConceptScore W2137397360C126322002 @default.
- W2137397360 hasConceptScore W2137397360C164705383 @default.
- W2137397360 hasConceptScore W2137397360C26635844 @default.
- W2137397360 hasConceptScore W2137397360C2776694085 @default.
- W2137397360 hasConceptScore W2137397360C2776755627 @default.
- W2137397360 hasConceptScore W2137397360C2780114680 @default.
- W2137397360 hasConceptScore W2137397360C42219234 @default.
- W2137397360 hasConceptScore W2137397360C500558357 @default.
- W2137397360 hasConceptScore W2137397360C541997718 @default.
- W2137397360 hasConceptScore W2137397360C57900726 @default.
- W2137397360 hasConceptScore W2137397360C71924100 @default.
- W2137397360 hasConceptScore W2137397360C84393581 @default.
- W2137397360 hasIssue "4" @default.
- W2137397360 hasLocation W21373973601 @default.
- W2137397360 hasLocation W21373973602 @default.
- W2137397360 hasOpenAccess W2137397360 @default.
- W2137397360 hasPrimaryLocation W21373973601 @default.
- W2137397360 hasRelatedWork W1973727166 @default.
- W2137397360 hasRelatedWork W1984169195 @default.
- W2137397360 hasRelatedWork W2028222475 @default.
- W2137397360 hasRelatedWork W2038431573 @default.
- W2137397360 hasRelatedWork W2049397185 @default.
- W2137397360 hasRelatedWork W2399063111 @default.
- W2137397360 hasRelatedWork W2409049948 @default.
- W2137397360 hasRelatedWork W2589123251 @default.
- W2137397360 hasRelatedWork W2901272624 @default.
- W2137397360 hasRelatedWork W3030971439 @default.
- W2137397360 hasVolume "137" @default.
- W2137397360 isParatext "false" @default.
- W2137397360 isRetracted "false" @default.